ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)
China · Delayed Price · Currency is CNY 38.89
-0.20 (-0.51%)
Feb 4, 2026, 10:14 AM CST
ChengDu ShengNuo Biotec Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 633.36 | 451.08 | 431.32 | 386.88 | 369.3 | 376.31 |
Other Revenue | 4.99 | 4.99 | 3.7 | 8.84 | 17.23 | 2.46 |
| 638.35 | 456.07 | 435.02 | 395.72 | 386.53 | 378.77 | |
Revenue Growth (YoY) | 32.54% | 4.84% | 9.93% | 2.38% | 2.05% | 15.93% |
Cost of Revenue | 288.44 | 201.61 | 163.38 | 142.39 | 110.67 | 84.87 |
Gross Profit | 349.91 | 254.46 | 271.64 | 253.33 | 275.86 | 293.9 |
Selling, General & Admin | 126.85 | 127.76 | 161.01 | 157.82 | 190.73 | 212.39 |
Research & Development | 56.94 | 49.17 | 29.05 | 23.29 | 13.75 | 18.25 |
Other Operating Expenses | 4.84 | 3.11 | 1.24 | 4.72 | 4.8 | 4.25 |
Operating Expenses | 192.38 | 188.4 | 194.37 | 188.29 | 210.14 | 236.08 |
Operating Income | 157.53 | 66.06 | 77.27 | 65.04 | 65.71 | 57.82 |
Interest Expense | -15.12 | -11.8 | -9.08 | -3.24 | -0.17 | -0.02 |
Interest & Investment Income | 3.76 | 3.75 | 3.92 | 4.57 | 4.2 | 1.53 |
Currency Exchange Gain (Loss) | 0.78 | 0.78 | 0.5 | 3 | -0.67 | -0.12 |
Other Non Operating Income (Expenses) | -1.86 | -0.21 | -0.29 | -1.55 | -0.5 | -0.12 |
EBT Excluding Unusual Items | 145.08 | 58.57 | 72.33 | 67.82 | 68.58 | 59.1 |
Gain (Loss) on Sale of Investments | - | 0.16 | -1.42 | - | - | - |
Gain (Loss) on Sale of Assets | -0.59 | -0.59 | -0.91 | -0.39 | -4.89 | -0.32 |
Asset Writedown | -4.6 | - | - | - | - | - |
Other Unusual Items | 3.37 | 3.37 | 10.12 | 4.93 | 6.8 | 10.11 |
Pretax Income | 143.26 | 61.51 | 80.12 | 72.36 | 70.49 | 68.88 |
Income Tax Expense | 23.27 | 11.67 | 9.8 | 7.88 | 9.24 | 8.88 |
Earnings From Continuing Operations | 119.99 | 49.84 | 70.32 | 64.48 | 61.25 | 60 |
Minority Interest in Earnings | 0.1 | 0.19 | 0.01 | - | - | - |
Net Income | 120.09 | 50.02 | 70.34 | 64.48 | 61.25 | 60 |
Net Income to Common | 120.09 | 50.02 | 70.34 | 64.48 | 61.25 | 60 |
Net Income Growth | 29.84% | -28.88% | 9.08% | 5.28% | 2.09% | 24.65% |
Shares Outstanding (Basic) | 156 | 156 | 156 | 156 | 141 | 118 |
Shares Outstanding (Diluted) | 161 | 159 | 159 | 156 | 141 | 118 |
Shares Change (YoY) | 1.78% | 0.22% | 2.03% | 10.21% | 20.10% | -0.00% |
EPS (Basic) | 0.77 | 0.32 | 0.45 | 0.41 | 0.43 | 0.51 |
EPS (Diluted) | 0.75 | 0.31 | 0.44 | 0.41 | 0.43 | 0.51 |
EPS Growth | 27.57% | -29.04% | 6.90% | -4.47% | -14.99% | 24.99% |
Free Cash Flow | -117.14 | -222.2 | -193.2 | -40.23 | -11.81 | 28.89 |
Free Cash Flow Per Share | -0.73 | -1.40 | -1.22 | -0.26 | -0.08 | 0.25 |
Dividend Per Share | 0.132 | 0.100 | 0.143 | 0.128 | 0.153 | - |
Dividend Growth | -7.80% | -30.02% | 11.99% | -16.66% | - | - |
Gross Margin | 54.81% | 55.79% | 62.44% | 64.02% | 71.37% | 77.59% |
Operating Margin | 24.68% | 14.49% | 17.76% | 16.44% | 17.00% | 15.27% |
Profit Margin | 18.81% | 10.97% | 16.17% | 16.30% | 15.85% | 15.84% |
Free Cash Flow Margin | -18.35% | -48.72% | -44.41% | -10.17% | -3.06% | 7.63% |
EBITDA | 195.58 | 99.66 | 104.92 | 88.77 | 83.65 | 74.89 |
EBITDA Margin | 30.64% | 21.85% | 24.12% | 22.43% | 21.64% | 19.77% |
D&A For EBITDA | 38.05 | 33.59 | 27.65 | 23.72 | 17.94 | 17.07 |
EBIT | 157.53 | 66.06 | 77.27 | 65.04 | 65.71 | 57.82 |
EBIT Margin | 24.68% | 14.49% | 17.76% | 16.44% | 17.00% | 15.27% |
Effective Tax Rate | 16.25% | 18.98% | 12.23% | 10.89% | 13.10% | 12.90% |
Revenue as Reported | 638.35 | 456.07 | 435.02 | 395.72 | 386.53 | 378.77 |
Advertising Expenses | - | 1.92 | 0.5 | 0.09 | 0.18 | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.